Skip to content

Honey and Nigella Sativa in COVID-19 Prophylaxis

Honey and Nigella Sativa in the Prophylaxis of COVID-19: A Randomized Controlled Trial

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04767087
Acronym
HNS-COVID-PK
Enrollment
1000
Registered
2021-02-23
Start date
2021-03-05
Completion date
2022-04-15
Last updated
2021-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

Honey, Nigella sativa, Prophylaxis, COVID-19, Prophetic Medicine

Brief summary

Honey and Nigella sativa has established antiviral, antibacterial, anti-inflammatory, and immunomodulatory roles. So it is planned to test for its prophylaxis

Interventions

DRUGHoney

0.5 gm/Kg/day honey

40 mg/Kg/day

OTHERPlacebo

empty capsule with sugar water

Sponsors

Sohaib Ashraf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Health care professionals Post-exposure COVID-19

Exclusion criteria

* Multi-organ failure active COVID-19

Design outcomes

Primary

MeasureTime frameDescription
SARS-CoV-2 infection rate14 daysRT-PCR SARS-CoV-2

Countries

Pakistan

Contacts

Primary ContactSohaib Ashraf, MBBS
sohaib@skzmdc.edu.pk8573167995
Backup ContactAhmad Imran, MBBS
ahmad.imran@skzmdc.edu.pk+923338110708

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026